COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,003 Articles (22,627 medRxiv, 8,376 bioRxiv)

Most recent first Previous |  Page 558: Articles 5571-5580  | Next

Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative study: A systematic review and meta-analysis
Tsang, T., Sullivan, S., Huang, X., Wang, C., Wang, Y., Nealon, J., Yang, B., Ainslie, K. E. C., Cowling, B. J.
10.1101/2022.11.03.22281925 — Posted: 2022-11-04
Unsupervised clustering of SARS-CoV-2 positive hospitalized patients identifies six endophenotypes of COVID-19 and points to FGFR and SHC4-signaling in acute respiratory distress syndrome
Ma, W., Soule, A., Liu, K., Allard, C., Tremblay, K., Rousseau, S., Emad, A.
10.1101/2022.11.02.22281834 — Posted: 2022-11-04
Estimating the gendered impact of COVID-19
Singh, S., Singh, R. K.
10.1101/2022.11.02.22276012 — Posted: 2022-11-04
Rapid onset of chronic urticaria after Moderna COVID-19 booster vaccine
Duperrex, O., Tommasini, F., Muller, Y.
10.1101/2022.11.03.22281730 — Posted: 2022-11-04
Evaluation of antibody kinetics and durability in health subjects vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
Zhang, H., Hua, Q., Xu, N., Zhang, X., Chen, B., Ma, X., Hu, J., Chen, Z., Yu, P., Lei, H., Wang, S., Ding, L., Fu, J., Liao, Y., Yang, J., Jiang, J., Lv, H.
10.1101/2022.11.03.515011 — Posted: 2022-11-04
Population-based sero-epidemiological estimates of real-world vaccine effectiveness against Omicron infection in an infection-naive population, Hong Kong, January to July 2022
Lau, J. J., Cheng, S. M., Leung, K., Lee, C. K., Hachim, A., Tsang, L. C., Yam, K. W., Chaothai, S., Kwan, K. K., Chai, Z. Y., Lo, T. H., Mori, M., Wu, C., Valkenburg, S. A., Amarasinghe, G. K., Lau, E. H., Hui, D. S., Leung, G. M., Peiris, M., Wu, J. T.
10.1101/2022.11.01.22281746 — Posted: 2022-11-04
Antiviral effect of candies containing persimmon-derived tannin against SARS-CoV-2 delta strain
Furukawa, R., Kitabatake, M., Ouji-Sageshima, N., Tomita, D., Kumamoto, M., Suzuki, Y., Nakano, A., Nakano, R., Matsumura, Y., Kayano, S.-i., Yano, H., Tamaki, S., Ito, T.
10.1101/2022.10.31.513793 — Posted: 2022-11-04
Spatial Optimization to Improve COVID-19 Vaccine Allocation
Goodson, J., Scroggins, S., Afroze, T., Shacham, E.
10.1101/2022.10.30.22281737 — Posted: 2022-11-04
Use of Interviewer-Administered Telephone Surveys during Infectious Disease Outbreaks, Epidemics, and Pandemics: A Scoping Review
Arita, S., Ba, M. F., Traore, Z., Bonnet, E., Faye, A., Ridde, V.
10.1101/2022.11.01.22281787 — Posted: 2022-11-03
COVID-19 and non-Hodgkins lymphoma: a common susceptibility pattern?
Sara, D. M., Minelli, C., Broccia, G., Vineis, P., Cocco, P.
10.1101/2022.11.01.22281794 — Posted: 2022-11-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).